...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: "expert market"??

Zenith is so cheap at the moment even though it isn't really liquid.  RVX isn't really liquid for most of us either as we are unwilling to take a huge haircut.  I hold both and will probably hold them until they do something (possible) or fail totally. (Often seems most likely)

 

So, not sure what you paid for RVX but if you are like many of us you have already lost at least the same amount of money per share as Zenith trades at.  Good money after bad?  Possibly.  GLTA

 

BTW I own both companies as well as some RVX warrants that are good until 2023.  All previous warrants have expired worthless but......

Share
New Message
Please login to post a reply